Intranasal parainfluenza virus type 5 (PIV5)–vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study

Respiratory syncytial virus (RSV) can lead to serious disease in infants, and no approved RSV vaccine is available for infants. This first in-human clinical trial evaluated a single dose of BLB201, a PIV5-vectored RSV vaccine administrated via intranasal route, for safety and immunogenicity in RSV-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Spearman, Paul, Jin, Hong, Knopp, Kristeene, Xiao, Peng, Gingerich, Maria Cristina, Kidd, Jamie, Singh, Karnail, Tellier, Marinka, Radziewicz, Henry, Wu, Samuel, McGregor, Matthew, Freda, Barbara, Wang, Zhaoti, John, Susan P., Villinger, Francois J., He, Biao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599610/
https://www.ncbi.nlm.nih.gov/pubmed/37878713
http://dx.doi.org/10.1126/sciadv.adj7611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599610/
https://www.ncbi.nlm.nih.gov/pubmed/37878713
http://dx.doi.org/10.1126/sciadv.adj7611

Ejemplares similares